Joanne F. Dorgan, Laura Baglietto, Louise A. Brinton, Anne Zeleniuch-Jacquotte, Helena Schock, Annika Idahl, Roni T. Falk, Ruth C. Travis, Antonia Trichopoulou, N. Charlotte Onland-Moret, Vittorio Krogh, Yutang Gao, Naomi Allen, Eva Lundin, Kathy J. Helzlsouer, Brian L. Egleston, Kala Visvanathan, Anne Tjønneland, Carlotta Sacerdote, Shelley S. Tworoger, Alan A. Arslan, Seungyoun Jung, Sabina Rinaldi, Melissa A. Merritt, Aurelio Barricarte, Paul N. Staats, Patrick M. Sluss, Renée T. Fortner, Xiao-Ou Shu, Rudolph Kaaks, Elisabete Weiderpass
Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend: 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity: ≥ 0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity: ≥ 0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer. This article is protected by copyright. All rights reserved.